Johnson & Johnson Patents Screening Method for Skin Treatment Regimen in Infants

US Patent No. 11,642,300 B2 (Kimberly Capone, Janeta Nikolovski, Lorena Telofski, Georgios Stamatas); Johnson & Johnson Consumer Inc., Skillman, NJ, has patented a minimally invasive method of screening a skin treatment regimen, ingredient and/or composition for benefit to skin of infants. It entails:

• measuring the level of one or more small molecule metabolites in an area of skin of an infant prior to application of the skin treatment regimen, ingredient and/or composition, wherein the one or more small molecule metabolites is a gamma-glutamyl amino acid selected from the group consisting of gamma-glutamyl-epsilon-lysine and gamma-glutamylglutamine;

• applying the skin treatment regimen, ingredient and/or composition to the area of skin of said infant for a period of time;

• measuring the level of the said one or more small molecule metabolites after the skin treatment regimen, ingredient and/or composition application.

The skin treatment regimen, ingredient and/or composition is of benefit to skin if within a confidence level of greater than 90% the level of the one or more small molecule metabolites changes vs. the no treatment control.